Q4 2022 EPS Estimates for Thermo Fisher Scientific Inc. (NYSE:TMO) Cut by Analyst

Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) – Analysts at SVB Leerink dropped their Q4 2022 earnings estimates for shares of Thermo Fisher Scientific in a report issued on Friday, January 6th. SVB Leerink analyst P. Souda now expects that the medical research company will post earnings per share of $5.16 for the quarter, down from their previous forecast of $5.17. SVB Leerink has a “Outperform” rating and a $620.00 price objective on the stock. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.04 per share. SVB Leerink also issued estimates for Thermo Fisher Scientific’s FY2024 earnings at $25.89 EPS.

TMO has been the topic of several other reports. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $711.00 to $696.00 and set an “outperform” rating on the stock in a research report on Thursday, October 27th. Deutsche Bank Aktiengesellschaft began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 13th. They set a “buy” rating and a $620.00 price target for the company. Royal Bank of Canada began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 6th. They set an “outperform” rating and a $661.00 price target for the company. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $525.00 to $505.00 and set an “underweight” rating for the company in a report on Tuesday, January 3rd. Finally, Barclays cut their price target on shares of Thermo Fisher Scientific from $575.00 to $570.00 and set an “overweight” rating for the company in a report on Tuesday, November 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $627.30.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $535.00 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.22 and a current ratio of 1.74. The firm’s 50-day simple moving average is $539.47 and its 200-day simple moving average is $544.93. Thermo Fisher Scientific has a twelve month low of $475.77 and a twelve month high of $631.89. The firm has a market cap of $209.82 billion, a P/E ratio of 30.07, a price-to-earnings-growth ratio of 1.87 and a beta of 0.83.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last issued its earnings results on Wednesday, October 26th. The medical research company reported $5.08 earnings per share for the quarter, beating the consensus estimate of $4.78 by $0.30. Thermo Fisher Scientific had a net margin of 15.92% and a return on equity of 22.97%. The business had revenue of $10.68 billion for the quarter, compared to analyst estimates of $9.86 billion.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Thermo Fisher Scientific by 168.1% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,014,472 shares of the medical research company’s stock valued at $1,094,244,000 after buying an additional 1,262,989 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 394.8% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,110,504 shares of the medical research company’s stock valued at $563,237,000 after buying an additional 886,075 shares during the period. Ontario Teachers Pension Plan Board acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $433,169,000. Jennison Associates LLC boosted its holdings in shares of Thermo Fisher Scientific by 416.0% in the second quarter. Jennison Associates LLC now owns 651,227 shares of the medical research company’s stock valued at $353,799,000 after buying an additional 525,014 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $209,946,000. Institutional investors and hedge funds own 85.92% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 8,200 shares of the business’s stock in a transaction that occurred on Thursday, November 3rd. The shares were sold at an average price of $487.45, for a total transaction of $3,997,090.00. Following the completion of the sale, the chief executive officer now directly owns 178,005 shares of the company’s stock, valued at $86,768,537.25. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $509.97, for a total transaction of $5,099,700.00. Following the completion of the transaction, the chief executive officer now owns 178,005 shares in the company, valued at $90,777,209.85. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 8,200 shares of the business’s stock in a transaction that occurred on Thursday, November 3rd. The shares were sold at an average price of $487.45, for a total transaction of $3,997,090.00. Following the transaction, the chief executive officer now owns 178,005 shares of the company’s stock, valued at approximately $86,768,537.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,475 shares of company stock valued at $16,073,443. Insiders own 0.43% of the company’s stock.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Thursday, November 10th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date of this dividend is Wednesday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.75%.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.